文献速递头颈与中枢神经肿瘤

帕博利珠单抗在程序性死亡配体1阳性鼻咽癌患者中的安全性和抗肿瘤活性:KEYNOTE-028研究结果

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
PubMed 文献 · J Clin Oncol · 2017-08-24

KEYNOTE-028是一项非随机、多队列、Ib期试验,评估帕博利珠单抗在程序性死亡配体1(PD-L1)阳性晚期实体瘤中的表现。鼻咽癌队列纳入27例复发或转移性鼻咽癌患者,接受帕博利珠单抗10 mg/kg每2周一次治疗,客观缓解率为25.9%(95%CI 11.1至46.3),中位随访20个月,≥3级药物相关不良事件发生率为29.6%,出现1例药物相关死亡(脓毒症)。结论认为帕博利珠单抗在该人群中显示出抗肿瘤活性和可控的安全性。

要点

  • PD-L1阳性复发或转移性鼻咽癌患者接受帕博利珠单抗治疗的客观缓解率为25.9%(95%CI 11.1至46.3)。
  • 部分缓解7例,疾病稳定14例,中位随访20个月。
  • ≥3级药物相关不良事件发生于8例(29.6%),出现1例药物相关死亡(脓毒症)。

核心结论

  • 帕博利珠单抗在复发或转移性PD-L1阳性鼻咽癌患者中显示出抗肿瘤活性和可控的安全性。

研究设计与样本

  • KEYNOTE-028(NCT02054806)是一项非随机、多队列、Ib期试验,评估帕博利珠单抗在PD-L1阳性晚期实体瘤患者中的表现。
  • 鼻咽癌队列纳入27例患者,关键入组标准包括不可切除或转移性疾病、既往标准治疗失败、PD-L1在1%或以上的肿瘤细胞或肿瘤浸润淋巴细胞中表达。
  • 患者接受帕博利珠单抗10 mg/kg每2周一次,最多2年,直至疾病进展或出现不可接受的毒性。
  • 主要终点为研究者评估的客观缓解率,肿瘤反应按RECIST 1.1版每8周评估一次(前6个月),之后每12周评估一次。

主要发现

  • 27例患者接受了帕博利珠单抗治疗,中位年龄52.0岁(范围18至68岁),92.6%曾接受过复发或转移性鼻咽癌的治疗,70.4%接受过三种或以上治疗。
  • 部分缓解7例,疾病稳定14例,客观缓解率为25.9%(95%CI 11.1至46.3),中位随访20个月;中心评估的客观缓解率相似(26.3%)。
  • 发生率在15%或以上的药物相关不良事件包括皮疹(25.9%)、瘙痒(25.9%)、疼痛(22.2%)、甲状腺功能减退(18.5%)和乏力(18.5%)。
  • ≥3级药物相关不良事件发生于8例患者(29.6%),出现1例药物相关死亡(脓毒症)。
  • 截至数据截止日期(2016年6月20日),2例患者仍在接受帕博利珠单抗治疗。

关键数值与推荐

  • PD-L1表达定义为在1%或以上的肿瘤细胞或肿瘤浸润淋巴细胞中表达。
  • 帕博利珠单抗给药方案为10 mg/kg每2周一次,最多2年。
  • 客观缓解率按RECIST 1.1版评估,每8周一次(前6个月),之后每12周一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To establish the safety profile and antitumor activity of the anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that expressed programmed death-ligand 1 (PD-L1). Patients and Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors. Key eligibility criteria for the NPC cohort included unresectable or metastatic disease, failure on prior standard therapy, and PD-L1 expression in 1% or more of tumor cells or tumor-infiltrating lymphocytes. Patients received pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR) per investigator review. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) every 8 weeks for the first 6 months and every 12 weeks thereafter. Results Twenty-seven patients received pembrolizumab. Median age was 52.0 years (range, 18 to 68 years); 92.6% received prior therapies for RM-NPC; 70.4% had received three or more therapies. Partial response and stable disease were observed in seven and 14 patients, respectively, for an ORR of 25.9% (95% CI, 11.1 to 46.3) over a median follow-up of 20 months. ORR by central review was similar (26.3%). Drug-related adverse events that occurred in 15% or more of patients included rash (25.9%), pruritus (25.9%), pain (22.2%), hypothyroidism (18.5%), and fatigue (18.5%). Grade ≥ 3 drug-related adverse events occurred in eight patients (29.6%), and there was one drug-related death (sepsis). As of the data cutoff (June 20, 2016), two patients remained on pembrolizumab treatment. Conclusion Pembrolizumab demonstrated antitumor activity and a manageable safety profile in patients with RM-NPC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hsu C, Lee SH, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017. PMID: 28837405. doi:10.1200/JCO.2017.73.3675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。